New Release: Australian Prescriber April Issue
Explore the new Australian Prescriber issue: Volume 47 Issue 2.
The new release of Australian Prescriber covers biologic treatments for severe asthma, obstructive sleep apnoea management, the 2023 Australian Guideline for Assessing and Managing Cardiovascular Disease Risk, and partnered pharmacist medication charting and prescribing models in Australian hospitals.
Explore the April issue:
- Biologic therapies for severe asthma
- Partnered pharmacist charting and prescribing
- Obstructive sleep apnoea in adults
- 2023 Australian Guidelines for Assessing and Managing Cardiovascular Disease Risk
New drugs:
- Andusomeran and raxtozinameran for prevention of COVID-19 disease
- Faricimab for neovascular age-related macular degeneration and diabetic macular oedema
- Relugolix+estradiol+norethisterone for treatment of symptomatic uterine fibroids
Letters to the Editor:
Australian Prescriber is Australia’s free, national, independent peer-reviewed journal providing critical commentary on drugs and therapeutics. Published bimonthly, it supports health professionals to make informed choices when prescribing.
The next Australian Prescriber podcast episode will be released on 30 April 2024. If you haven’t already, listen to the latest episodes on Managing hypercholesterolaemia and on Ongoing challenges of off-label prescribing.
Are you a subscriber? Get the latest updates for free. Subscribe now.
Published 24/04/2024